ASCO

The combination of sacituzumab govitecan (Trodelvy®; Gilead Sciences; See ADC Drugmap)* + pembrolizumab (Keytruda®; Merck & Co/MSD) reduced the risk of disease progression or death by 35% (HR: 0.65) versus standard of care (SoC) pembrolizumab plus chemotherapy in first-line treatment for patients with PD-L1+ (CPS ≥10) metastatic triple-negative breast cancer (TNBC).

The international phase 3 DESTINY-Gastric04 clinical trial (NCT04704934), sponsored  by Daiichi Sankyo, found that second-line treatment with trastuzumab deruxtecan (Enhertu®; also known as T-DXd; DS-8201; Daiichi Sankyo and AstraZeneca, See ADC Drugmap) can help people with advanced human epidermal growth factor receptor 2 (HER2-) positive (IHC 3+ or IHC 2+/ISH+) unresectable and/or metastatic gastric or gastroesophageal junction adenocarcinoma (GEJA) that have grown during first-line treatment live about 3 months longer. The study outcomes demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) compared to ramucirumab (Cyramza®; Eli Lilly and Company) plus paclitaxel (Taxol®; Bristol-Myers Squibb).

Daiichi Sankyo and Merck & CO/MSD have voluntarily withdrawn the Biologics License Application (BLA) seeking accelerated approval in the U.S. for patritumab deruxtecan (HER3-DXd) in patients with previously treated locally advanced or metastatic EGFR-mutated Non-Small Cell Lung Cancer (NSCLC) previously treated with two or more systemic therapies.

ASCO 2025: EMD Serono to Highlight Encouraging Early Data for Precemtabart Tocentecan in Colorectal

During the upcoming annual meeting of the American Society of Clinical Oncology (ASCO) which will take place May 30 – June 3, 2025, in Chicago, Illinois, Rakuten Medical* will be presenting a Trial in Progress poster with updates of the company's ongoing global Phase 3 clinical trial evaluating ASP-1929 photoimmunotherapy in combination with the anti-PD-1 pembrolizumab (Keytruda®; Merck & Co / MSD) as a first-line therapy for patients with recurrent head and neck squamous cell carcinoma (HNSCC).

FDA Grants Fast Track Designation ADRX-0706, a Nectin-4 ADC for the Treatment of Advanced Cervical Cancer

Initial dose escalation results from its ongoing Phase 1 KisMET-01 study evaluating the investigational 'next generation' cMET-targeting Antibody-drug Conjugates (ADC), MYTX-011, in patients with...

Detailed overall survival (OS) results from the ongoing, randomized, double-blind, multicenter Phase 3 ECHELON-3 study (NCT04404283) investigating brentuximab vedotin (Adcetris®; Pfizer*/Takeda) in combination with...

ASCO 2024: A More Effective Treatment Combination for Hodgkin Lymphoma

New data from AbbVie's innovative antibody-drug conjugate (ADC) platform will be showcased across three oral presentations at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting (May 31 - June 4, 2024).